<?xml version="1.0" encoding="UTF-8"?>
<p id="p0175">
 <bold>MS Exacerbation:</bold> Early insights about COVID-19 in MS patients suggest that the risk of infection and associated morbidity in this population is not significantly different from the non-COVID19 patients [
 <xref rid="bb0650" ref-type="bibr">130</xref>] Moreover, worsening outcome with regards to with disease-modifying therapies has not been reported. [
 <xref rid="bb0655" ref-type="bibr">131</xref>]
</p>
